Patent assignee · US · COMPANY

Arrowhead Pharmaceuticals, Inc.

🏢 View company profile →
93Patents
93Active
93Granted
53Portfolio score

Filing activity: Jan 8, 2013 → Mar 20, 2024

Most-cited patents

PatentTitleAreaCited byStatus
US10130651B2 RNAi Therapy for Hepatitis B Virus Infection Emerging Cross-Sectional Technologies 17 Active
US9796756B2 Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA Chemistry; Metallurgy 15 Active
US10294474B2 Targeting ligands Chemistry; Metallurgy 13 Active
US9803205B2 Compositions and methods for inhibiting gene expression of factor XII Chemistry; Metallurgy 9 Active
US10450565B2 Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use Physics 7 Active
US10662427B2 Compositions and methods for inhibiting gene expression of LPA Chemistry; Metallurgy 5 Active
US10246709B2 Targeting ligands for therapeutic compounds Chemistry; Metallurgy 5 Active
US10240153B2 Organic compositions to treat APOC3-related diseases Chemistry; Metallurgy 4 Active
US10780108B2 RNAi agents for Hepatitis B virus infection Emerging Cross-Sectional Technologies 4 Active
US9932586B2 Compositions and methods for inhibiting gene expression of LPA Chemistry; Metallurgy 3 Active
US9868949B2 Organic compositions to treat EPAS1-related diseases Chemistry; Metallurgy 3 Active
US10597657B2 RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) Chemistry; Metallurgy 3 Active
US10308941B2 Compositions and methods for inhibiting gene expression of factor XII Chemistry; Metallurgy 3 Active
US10006025B2 Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin Chemistry; Metallurgy 3 Active
USRE48345E1 Compositions and methods for inhibiting gene expression of hepatitis B virus General 3 Active
US10806750B2 RNAi therapy for hepatitis B virus infection Emerging Cross-Sectional Technologies 3 Active
US9976141B2 Compositions and methods for inhibiting gene expression of Hif2alpha Chemistry; Metallurgy 3 Active
US9540643B2 Organic compositions to treat HSF1-related diseases Emerging Cross-Sectional Technologies 2 Active
US11384355B2 Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin Chemistry; Metallurgy 2 Active
US9526796B2 Peptide-based in vivo siRNA delivery system Chemistry; Metallurgy 2 Active
US11174481B2 Targeting ligands Chemistry; Metallurgy 2 Active
US10287582B2 Organic compositions to treat HSF1-related diseases Emerging Cross-Sectional Technologies 2 Active
US11203756B2 Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use Physics 2 Active
US9476052B2 RNAi inhibition of alpha-ENaC expression Chemistry; Metallurgy 2 Active
US9453220B2 RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders Chemistry; Metallurgy 1 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.